Bloomberg -- Novartis AG won European Union regulatory backing for its multiple sclerosis drug Gilenya, beating Merck KGaA in a race to sell a pill to slow the crippling disease.
Bloomberg -- Novartis AG won European Union regulatory backing for its multiple sclerosis drug Gilenya, beating Merck KGaA in a race to sell a pill to slow the crippling disease.
